PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
October 24, 2025 11:39 ET | Source: PMV Pharmaceuticals, Inc. Data presented…
Search
Tag: y220c
